Johnson & Johnson Aktie
149,19USD | -1,28USD | -0,85% |
WKN: 853260 / ISIN: US4781601046
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 99,88 |
The Vanguard Group, Inc. | 9,53 |
Vanguard Group, Inc. (Subfiler) | 9,15 |
State Street Corp. | 5,58 |
SSgA Funds Management, Inc. | 5,52 |
Vanguard Total Stock Market ETF | 3,16 |
BlackRock Fund Advisors | 3,11 |
Vanguard 500 Index Fund | 2,65 |
Geode Capital Management LLC | 2,33 |
BlackRock Institutional Trust Co. NA | 2,21 |
State Farm Investment Management Corp. | 1,32 |
Fidelity 500 Index Fund | 1,23 |
Norges Bank (13F) | 1,21 |
iShares Core S&P 500 ETF | 1,11 |
Morgan Stanley Smith Barney LLC | 0,98 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 132 200 | 134 500 | 141 700 | 152 700 | 131 900 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,62 | 0,61 | 0,66 | 0,62 | 0,65 |
Bilanz (in Mio. USD) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 45 274 | 51 237 | 60 979 | 55 294 | 53 495 |
Summe Anlagevermögen | 112 454 | 123 657 | 121 039 | 132 084 | 114 063 |
Summe Aktiva | 157 728 | 174 894 | 182 018 | 187 378 | 167 558 |
Bilanz (in Mio. USD) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Fremdkapital | 98 257 | 111 616 | 107 995 | 110 574 | 98 784 |
Summe Eigenkapital | 59 471 | 63 278 | 74 023 | 76 804 | 68 774 |
Summe Passiva | 157 728 | 174 894 | 182 018 | 187 378 | 167 558 |
Adresse
One Johnson & Johnson Plaza, 08933 New Brunswick | |
Telefon | +1 (732) 524-0400 |
Internet | http://www.jnj.com |
Management
Anne M. Mulcahy
Independent Director |
Caroline Tillett
Global Head-Consumer Health |
Darius Adamczyk
Independent Director |
Elizabeth Forminard
Executive Vice President & General Counsel |
Eugene A. Woods
Independent Director |
George Davy
Global HR Director |
Hubert Joly
Independent Director |
James D. Swanson
Chief Information Officer & Executive VP |
Jennifer A. Doudna
Independent Director |
Jennifer L. Taubert
EVP & Worldwide Chairman-Innovative Medicine |
Jessica Moore
Vice President-Investor Relations |
Joaquin Duato
Chairman & Chief Executive Officer |
John C. Reed
Executive Vice President-Innovative Medicine |
Jonathan Sheh
Director-Workplace Experience |
Joseph J. Wolk
Chief Financial Officer & Executive Vice President |
Juliana Clawson
Head-Global Quality & Compliance |
Kathryn E. Wengel
Chief Technical Operations & Risk Officer |
Kristen Blair Mulholland
Chief Human Resources Officer & Executive VP |
Lisa Paley
Vice President-US Sales |
Marc Larkins
Secretary & Vice President-Governance |
Marillyn A. Hewson
Lead Independent Director |
Mark Alan Weinberger
Independent Director |
Mark B. McClellan
Independent Director |
Mary C. Beckerle
Independent Director |
Meredith Stevens
Vice President |
Michael Bzdak
Global Dir-Employee Engagement-Global Cmnty Impact |
Nadja Y. West
Independent Director |
Neil Ackerman
Head-Innovation, Global Supply & Transformation |
Paul Ruh
Chief Financial Officer-Consumer Health |
Paula A. Johnson
Independent Director |
Robert J. Decker
Chief Accounting Officer & Controller |
Ronald A. Kapusta
Chief Accounting Officer & Controller |
Thomas J. Spellman
Secretary |
Timothy Schmid
Executive Vice President & Chairman-Worldwide |
William E. Cohn
Vice President-Medical Devices |
William N. Hait
Chief External Innovation & Executive VP-Medical |